Title: Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
Authors: Sargent, D ×
Shi, Q
Yothers, G
Van Cutsem, Eric
Cassidy, J
Saltz, L
Wolmark, N
Bot, B
Grothey, A
Buyse, M
de Gramont, A #
Issue Date: May-2011
Publisher: Pergamon
Series Title: European Journal of Cancer vol:47 issue:7 pages:990-996
ISSN: 0959-8049
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Clinical Digestive Oncology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science